AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11963648
Drug: Reference micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference micronized formulation of fenofibrate (200 mg)
Trial: 2541159
Drug: Cortisol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (6 mg/h)
Trial: 30941975
Drug: Knowledge about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge about PCa treatment success
Trial: 27874307
Drug: Needle-free injection
RxNorm normalized name: Stratis Needle-Free Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-free injection device
Trial: 21947374
Drug: Combined spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spa therapy (mud packs and thermal baths) and rehabilitation (exercises in a thermal pool) for 10 sessions
Trial: 17542112
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Trial: 17542112
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Trial: 17542112
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Trial: 9169251
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin formulation
Trial: 9169251
Drug: Plain paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain paracetamol
Trial: 9169251
Drug: Soluble paracetamol
RxNorm normalized name: Disprol Soluble Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble paracetamol
Trial: 8192173
Drug: 0.5% podofilox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% podofilox self-administered twice daily for 3 consecutive days per week for 4 weeks (stage 1)
Trial: 8192173
Drug: 0.5% podofilox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% podofilox self-administered once daily for 3 days per week for 8 weeks (stage 2)
Trial: 3285883
Drug: Amoxycillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin‐clavulanic acid (1.2 g intravenous)
Trial: 3285883
Drug: Metronidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1 g suppository)
Trial: 22935052
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg orally three times daily for 28 days
Trial: 28107101
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Trial: 25742888
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg enalapril plus 0.8 mg FA (high‐FA group)
Trial: 25742888
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg enalapril (control group)
Trial: 25742888
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg enalapril plus 0.4 mg FA (low‐FA group)
Trial: 23004926
Drug: Methantheline bromide
RxNorm normalized name: methantheline bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methantheline bromide (MB) 50 mg three times daily
Trial: 24004119
Drug: Low-dose helical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose helical computed tomography (CT)
Trial: 10971659
Drug: 6-mg Sirdalud
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mg Sirdalud
Trial: 10971659
Drug: 12-mg Sirdalud
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-mg Sirdalud MR
Trial: 8884967
Drug: Conventional 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 5 days per week treatment (arm B)
Trial: 1571205
Drug: Prednisone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 40 mg/m2, given every other day as a single morning dose
Trial: 1571205
Drug: Lactose, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose, 40 mg/m2, given every other day as a single morning dose (Control)
Trial: 3880781
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of dimethylsulfoxide (DMSO) solution
Trial: 25005452
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg orally once daily
Trial: 25005452
Drug: Dose-adjusted oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted oral vitamin K antagonist (VKA)
Trial: 11879260
Drug: Sildenafil (100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100-mg single dose)
Trial: 9226059
Drug: loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loratadine (10 mg OD)
Trial: 7904786
Drug: Roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate (150 mg once daily)
Trial: 3523713
Drug: trimethoprim‐sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim‐sulfamethoxazole (160 mg/800 mg daily)
Trial: 3523713
Drug: trimethoprim (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim (200 mg daily)
Trial: 3523713
Drug: bicozamycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bicozamycin (500 mg four times daily)
Trial: 3523713
Drug: norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin (400 mg daily)
Trial: 23442897
Drug: Dialectical behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behaviour therapy
Trial: 29567630
Drug: Enalapril started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril started before chemotherapy (prevention arm)
Trial: 29567630
Drug: Enalapril started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril started only in patients with an increase in troponin during or after chemotherapy (troponin-triggered arm)
Trial: 29354992
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of cilostazol, 50 mg, twice a day for 4 sessions (2 weeks each session)
Trial: 25736283
Drug: Evacetrapib 130
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 130 mg/d following a high-fat breakfast
Trial: 25736283
Drug: Evacetrapib 130
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 130 mg/d following a 10-hour fast
Trial: 25736283
Drug: Evacetrapib 130
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 130 mg/d (both fed and fasted states)
Trial: 21178093
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) containing 2.5 mg iron as NaFeEDTA and 2.5 mg zinc, added to high-phytate maize porridge 5 days/week for 23 weeks
Trial: 19064623
Drug: RTS,S/AS02D vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02D vaccine
Trial: 10975476
Drug: Daily schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily schedule of plasmapheresis
Trial: 9368546
Drug: Early outpatient
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early outpatient treatment for PTSD for 6 months
Trial: 1391980
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with tamoxifen and medroxyprogesterone acetate
Trial: 29940126
Drug: Conventional subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subcutaneous insulin therapy
Trial: 25609011
Drug: Zovirax 200
RxNorm normalized name: Zovirax 200mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zovirax 200 mg dispersible tablets co-administered with 400 mg chitosan HCl
Trial: 25609011
Drug: Zovirax 200
RxNorm normalized name: Zovirax 200mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zovirax 200 mg dispersible tablets co-administered with 1000 mg chitosan HCl
Trial: 23400856
Drug: Color characters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Color characters (e.g., hong2, 'red')
Trial: 23400856
Drug: Homophones of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homophones of the color characters (S+T+) (e.g., hong2, 'flood')
Trial: 23400856
Drug: Different-tone homophones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different-tone homophones (S+T-) (e.g., hong1, 'boom')
Trial: 23400856
Drug: Characters that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Characters that shared the same tone but differed in segments with the color characters (S-T+) (e.g., ping2, 'bottle')
Trial: 23400856
Drug: Neutral characters
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral characters (S-T-) (e.g., qian1, 'leading through')
Trial: 21911098
Drug: Supportive individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive individual psychotherapy followed by combined psychodynamic and cognitive‐behavioral group therapy (total of 28 sessions).
Trial: 11134132
Drug: GHRP-2 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GHRP-2 administration
Trial: 8800308
Drug: Intravenous iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous iloprost 0.5‐2.0 ng/kg/min for 6 h from 8 to 13 days
Trial: 1464049
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin pre-treatment
Trial: 29433385
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine infusion (bolus 1.5 mg/kg followed by a continuous infusion at the rate of 2 mg/kg/hr until skin closure)
Trial: 29433385
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine infusion
Trial: 29433385
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl solution)
Trial: 25305156
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of imaging abnormalities (PiB+, small hippocampi, WMLs)
Trial: 16550311
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose bolus of tirofiban (10 microg/kg/3 min) with 24‐h infusion at a rate of 0.15 microg/kg/min
Trial: 16550311
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose bolus tirofiban (25 microg/kg/3 min)
Trial: 9305603
Drug: St Jude-type
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St Jude-type multiagent chemotherapy
Trial: 9305603
Drug: St Jude-type
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St Jude-type multiagent chemotherapy (for good-prognosis subgroup)
Trial: 8361895
Drug: Molsidomine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (2 mg, single oral dose)
Trial: 2423807
Drug: Indoramin plus
RxNorm normalized name: indoramin
DrugBank: Indoramin (DB08950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin plus thiazide diuretic (n = 157)
Trial: 26072289
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose escalation (RDE)
Trial: 26072289
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate brachytherapy boost (HDRB)
Trial: 18789492
Drug: JTT‐705 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTT‐705 600 mg/d
Trial: 16305570
Drug: Self-administered isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered isoflurane and desflurane
Trial: 31175903
Drug: Stereotactic Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic Body Radiation Therapy (SBRT) for recurrent HCC
Trial: 23985260
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy (FP/H)
Trial: 23985260
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (FP)
Trial: 16650294
Drug: Intrarectal application
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal application of 2% lidocaine gel
Trial: 16650294
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of midazolam and meperidine
Trial: 16650294
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sedation or analgesic)
Trial: 11530870
Drug: Dexamethasone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (24 mg divided into 4 doses 12 hours apart)
Trial: 11367651
Drug: Qingning Oral
RxNorm normalized name: PYRROLIDINYL DIAMINOPYRIMIDINE OXIDE 33 g in 100 mL / PANAX GINSENG WHOLE 33 g in 100 mL / DIAMINOPYRIMIDINE OXIDE 30 g in 100 mL / NIACINAMIDE 33 g in 100 mL INTRADERMAL LIQUID [QINGLIN ANTI DETACHMENT NURTURING HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingning Oral Liquid (QNOL) with conventional therapy, 10 ml three times a day for 30 days
Trial: 8150234
Drug: Cholecystokinin-33 infusion
RxNorm normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecystokinin-33 infusion (0.25 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Trial: 8150234
Drug: Cholecystokinin-33 infusion
RxNorm normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecystokinin-33 infusion (0.5 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Trial: 8150234
Drug: Cholecystokinin-33 infusion
RxNorm normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecystokinin-33 infusion (1.0 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Trial: 22617307
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + Proxelan for 28 days
Trial: 22617307
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for 28 days
Trial: 18544384
Drug: Local wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local wound infusion of 0.15% bupivacaine at 2 mL/h combined with intravenous patient-controlled analgesia
Trial: 18544384
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia alone with sham thoracotomy wound infusion of normal saline
Trial: 9988841
Drug: New antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antipsychotics (risperidone, olanzapine, sertindole, quetiapine)
Trial: 9988841
Drug: All new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All new antipsychotics
Trial: 7734250
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose group
Trial: 31590924
Drug: FAAH inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAAH inhibitor (PF‐04457845, 4 mg orally, once daily)
Trial: 27940278
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen (2 L/min via standard nasal prongs) during the 6-min walk test (6MWTO2)
Trial: 25661195
Drug: MK-7123 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7123 (30 mg, po, daily for 28 days)
Trial: 23417515
Drug: Ziprasidone 60
RxNorm normalized name: ziprasidone 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 60 mg twice daily
Trial: 21795435
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (0.12 g · kg(‐1) · h(‐1))
Trial: 17324660
Drug: Ginkgo biloba-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba-based supplement (160 mg ginkgo biloba, 68 mg gotu kola, and 180 mg DHA per day for 4 months)
Trial: 16442038
Drug: Onion extract
RxNorm normalized name: Onion Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion extract gel (Mederma) applied three times daily for 8 weeks
Trial: 16442038
Drug: Petrolatum-based emollient
RxNorm normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum-based emollient (Aquaphor) applied three times daily for 8 weeks
Trial: 9034695
Drug: Right unilateral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right unilateral (RUL) electroconvulsive therapy (ECT)
Trial: 1355427
Drug: alcohol (0.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcohol (0.72 g.kg‐1, lean body mass)
Trial: 6438504
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without initial angiography
Trial: 25628006
Drug: JDTic 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JDTic 1 mg
Trial: 16885722
Drug: Single 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10 mg oral dose of dronabinol (synthetic THC)
Trial: 16885722
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of THC (0.39, 0.47, and 14.8 mg THC in hemp oil and 7.5 mg dronabinol)
Trial: 15595301
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) 0.2 g Cr x kg(‐1) after exercise
Trial: 8390732
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving perioperative parenteral antibiotics only
Trial: 31664632
Drug: 80% Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% Aloe Vera gel
Trial: 31664632
Drug: 0.12% Chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% Chlorhexidine gel
Trial: 30581291
Drug: Dopamine (DA)-blocking
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (DA)-blocking drug
Trial: 28958469
Drug: Lenalidomide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (2.5 mg/day)
Trial: 28958469
Drug: Placebo (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.5 mg/day)
Trial: 24734355
Drug: 6 hours
RxNorm normalized name: nitroglycerin 0.6 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 hours Chlorhexidine (CHX) 0.5% oral decontamination
Trial: 24734355
Drug: 12 hours
RxNorm normalized name: PATCH, TRANSDERMAL 12 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 hours Chlorhexidine (CHX) 0.5% oral decontamination
Trial: 18000094
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg daily of micronized DHEA
Trial: 17095898
Drug: Topiramate (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (average dosage 5.2 mg/kg per day)
Trial: 12907482
Drug: Heroin plus
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin plus methadone (maximum 1000 mg heroin per day and 150 mg methadone per day)
Trial: 12907482
Drug: Injectable heroin
RxNorm normalized name: heroin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable heroin plus methadone (maximum 1000 mg heroin per day and 150 mg methadone per day)
Trial: 12907482
Drug: Methadone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone alone (maximum 150 mg per day)
Trial: 8682597
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 60-90 mg o.d.
Trial: 8682597
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 40-60 mg b.d.
Trial: 8682597
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 50-100 mg o.d.
Trial: 1992535
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (320 to 1,600 mg/d)
Trial: 31620886
Drug: Heat-killed Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed Lactobacillus plantarum L-137 (10 mg)
Trial: 22784345
Drug: Ginger combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger combination (340 mg EV.EXT 35 Zingiber officinalis extract)
Trial: 22784345
Drug: Diclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (100 mg daily)
Trial: 20357732
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (captopril and enalapril)